Comparative Pharmacology
Head-to-head clinical analysis: MEPRO ASPIRIN versus NAPROXEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPRO ASPIRIN versus NAPROXEN.
MEPRO-ASPIRIN vs NAPROXEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life.
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%).
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Category D/X
Category D/X
NSAID / Antiplatelet
NSAID